Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood

Platelets

Volumn 11, Issue 8, 2000, Pages 446-458

  Kikura, M ^a   Kazama, T ^a   Ikeda, T ^a   Sato, S ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; MILRINONE; PROSTAGLANDIN E1;

ARTICLE; BLOOD SAMPLING; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEMOSTASIS; HUMAN; HUMAN CELL; HYDROLYSIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR BINDING; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADULT; ALPROSTADIL; AMRINONE; CARDIOTONIC AGENTS; COLLAGEN; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; HUMANS; KINETICS; MALE; MIDDLE AGED; MILRINONE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; VASODILATOR AGENTS;

EID: 0034488545     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100020027824     Document Type: Article

References (55)

1. Intracoronary morphology of culprit lesions after reperfusion in acute myocardial infarction: Serial angioscopic observations
2. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly from coronary artery disease
3. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic death
4. Cyclic nucleotides in platelet function
5. Effect of PGE1 on platelet behaviour in vitro and in vivo
6. Inhibition of platelet energy production and release reaction by PGE1, theophylline and cAMP
7. Identification of glycoprotein Ibβ as one of the major proteins phosphorylated during exposure of intact platelets to agents that activate cAMP-dependent protein kinase
8. Platelet glycoprotein Ib beta is phosphorylated on serine 166 by cyclic AMP-dependent protein kinase
9. Cyclic AMP-dependent phosphorylation of filamen in mammalian smooth muscle
10. Human platelet myosin light chain kinase requires the calcium-binding protein calmodulin for activity
11. Relationship between cytoplasmic free calcium and myosin light chain phosphorylation in intact platelets
12. Inositol 1,4,5-triphosphate releases Ca2+ from a Ca2+-transporting membrane vesicle fraction derived from human platelets
13. A role for inositol triphosphate in intracellular Ca2+ mobilization and granule secretion in platelets
14. Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3′, 5′-cyclic monophosphate and protein kinase
15. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin
16. The influence of epinephrine on prostacyclin (PGI2) induced disaggregation of ADP aggregated platelets
17. Disaggregation and reaggregation of 'irreversibly' aggregated platelets: A method for more complete evaluation of anti-platelet drugs
18. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets
19. The effect of prostaglandin E1 on platelet function in vitro and in vivo
20. Divergent effects of epinephrine and prostaglandin E1 on levels of cyclic AMP in human blood platelets
21. The in vitro effect of amrinone on platelet aggregation in human whole blood
22. A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood
23. Effect of amrinone, a cardiotonic drug, on haemodynamics and platelet function
24. Effect of milrinone on human platelet shape change, aggregation and thromboxane A2 synthesis: An in vitro study
25. Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone
26. Disaggregatory action of phosphodiesterase inhibitors
27. Influence of sample collection and delay in study performance on test results
28. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue
29. Molecular basis for ADP-induced platelet activation
30. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors
31. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
32. Signaling through G proteins in platelets: To the integrins and beyond
33. Integrin signaling: The platelet paradigm
34. cAMP-dependent protein kinase. Model for an enzyme family
35. Signal transduction and intracellular regulatory processes in platelets
36. Effect of prostaglandin E1 alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3′:5′-cyclic monophosphate
37. Cyclic AMP and platelet function
38. Regulation of cyclic AMP levels and aggregation in human platelets by prostaglandin E
39. The effects of amrinone on human platelet aggregation: Evidence that amrinone does not act through a cyclic nucleotide mechanism in platelet rich plasma
40. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets
41. Reversibility of the association of fibrinogen with rabbit platelets exposed to ADP
42. Factors influencing the deaggregation of human and rabbit platelets
43. Inhibition of platelet aggregation and cytoplasmic calcium response by calcium antagonists: Studies with aequorin and quin2
44. Effects of inorganic ions and plasma proteins on the aggregation of blood platelets by adenosine diphosphate
45. ++-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis
46. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex
47. Aggregation of blood platelets by adenosine diphosphate and its reversal
48. The electronic aggregometer: A novel device for assessing platelet behavior in blood
49. Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin)
50. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents
51. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment
52. Critical evaluation of platelet aggregation in whole human blood
53. Evaluation of electrical aggregometry: Comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets
54. Evaluation of a new bipyridine inotropic agent - Milrinone - In patients with severe congestive heart failure
55. ++ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone